Introduction: Denosumab is known to increase bone mineral density (BMD) of both trabecular and cortical bones for as long as 10 years. However, no studies have compared the effects of denosumab on trabecular and cortical BMD in the same vertebral body. This study investigated one or more repeated quantitative computed tomography (QCT)s in patients with osteopenia/osteoporosis under the denosumab treatment for up to 8.7 years.
No takes yet. Share an insight, caveat, or question.
Harada et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: